Maximus (MMS) Down 33% YTD: Strong Guidance and Buybacks Contrast With Valuation Concerns
Key Takeaways
- Maximus shares have declined approximately 5.3% over the last 30 days, closing at $57.97 on July 15, 2026, extending a year-to-date decline of roughly 33%.
- The company continues to raise earnings guidance for fiscal 2026, now forecasting adjusted EPS between $8.25 and $8.55, supported by AI-driven automation and margin expansion.
- A refreshed $400 million share repurchase authorization and consistent $0.33 quarterly dividend underscore management's confidence in cash generation.
- Analysts maintain a consensus Buy rating with a price target of $105, implying over 80% upside from current levels, though market sentiment remains cautious.
- Government budget exposure and reliance on federal and state contracts remain the primary headwinds weighing on valuation.
Where MMS Stands in the Current Market
MMS closed at $57.97 on July 15, 2026, reflecting a roughly 5.3% decline from the June 16 closing price of $61.20. The stock has been under sustained pressure throughout 2026, with a year-to-date decline of approximately 33% and a 52-week range spanning from $52.73 to $100.00. Trading at a P/E ratio of roughly 8.2x — well below the professional services industry average of approximately 19.9x — Maximus screens as notably undervalued on a multiples basis. The company carries a market capitalization of approximately $3.05 billion and offers a forward dividend yield of 2.28%. Despite fundamentally solid earnings and an aggressive capital return program, broader concerns around government spending priorities and contract renewal risk have kept the stock under pressure.
Maximus Business Overview and Competitive Position
Maximus is a leading pure-play provider of business process management and technology-enabled services to government agencies worldwide. Founded in 1975 and headquartered in Tysons, Virginia, the company operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. Its core offerings include the administration of large-scale health insurance eligibility and enrollment programs, clinical assessments and appeals, unemployment insurance support, and technology solutions for public sector clients. With approximately 37,200 employees and trailing twelve-month revenue of $5.32 billion, Maximus generates predictable recurring revenue from long-term government contracts. The company's competitive moat is built on decades of domain expertise, established relationships with federal and state agencies, and an expanding suite of AI-enabled automation tools that improve productivity and margins across its programs. Key peers in the government services space include CACI and CNDT.
Recent Developments Shaping MMS
Several notable developments have shaped investor sentiment around Maximus in recent weeks. On July 6, 2026, the company declared a quarterly cash dividend of $0.33 per share, payable on August 31, reinforcing its commitment to shareholder returns. On July 9, Maximus scheduled its fiscal 2026 third-quarter earnings call for August 6, 2026, which will cover results for the period ending June 30, 2026, and serve as the next major catalyst.
Earlier in the year, the company delivered a strong fiscal second quarter, reporting adjusted diluted EPS of $2.07 and raising its full-year adjusted EBITDA margin guidance by 20 basis points to approximately 14.2%. Management also increased adjusted EPS guidance to a range of $8.25 to $8.55, citing growing confidence in AI and technology-driven efficiency gains. The Board authorized a $400 million share repurchase refresh, and the company repurchased 1.4 million shares for $111 million during the second quarter alone. Despite these positive operational signals, the stock has continued to decline, as the market weighs persistent concerns about federal budget exposure, slower growth in the U.S. Services segment, and elevated days sales outstanding (DSO) at 78 days as of March 31, 2026.
2026 Outlook and Key Metrics to Monitor
Looking ahead, the August 6, 2026, earnings release will be the nearest major catalyst for Maximus. Investors should pay close attention to management's updated commentary on the U.S. Federal Services segment margin trajectory, which improved to 17.6% in the second quarter and has been the company's strongest growth engine. The implementation timeline for the Working Families Tax Cut Act and potential new Medicaid community engagement requirements represent significant pipeline opportunities that could begin contributing to revenue in fiscal 2027 and beyond. On the risk side, any signs that government agencies are shifting toward in-house automation rather than outsourcing could pressure Maximus's contracted revenue base. Additionally, DSO normalization remains a key metric — management expects it to finish the fiscal year below 70 days. The company's below-peer P/E multiple and substantial analyst price target create a setup where any positive catalyst, particularly around new contract wins or improving cash conversion, could meaningfully shift sentiment. From what I see, this setup warrants close monitoring ahead of the earnings report.
Exploring Systematic AI Trading Approaches
For traders seeking systematic, data-driven approaches to navigate markets like the one affecting Maximus, I often review Tickeron's Trending AI Robots page for a curated view of top-performing AI trading bots. Tickeron operates hundreds of AI-powered trading bots that actively trade thousands of tickers across equities, ETFs, and forex, but only the highest-performing and most strategically relevant bots are featured in this section. These bots span a wide array of trading strategies — from swing trading and momentum-based approaches to longer-term trend-following models — and each bot's performance metrics, trade history, and strategy logic are transparently displayed for evaluation. Exploring the Trending AI Robots page can help investors identify automated strategies aligned with their risk tolerance and market outlook.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MMS's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for MMS moved out of oversold territory on July 02, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In of the 31 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 10, 2026. You may want to consider a long position or call options on MMS as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MMS just turned positive on July 07, 2026. Looking at past instances where MMS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MMS advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .
MMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MMS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.795) is normal, around the industry mean (15.678). P/E Ratio (8.704) is within average values for comparable stocks, (74.281). MMS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.460). Dividend Yield (0.022) settles around the average of (0.021) among similar stocks. P/S Ratio (0.612) is also within normal values, averaging (8.412).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of business process services to government health and human services agencies
Industry OfficeEquipmentSupplies
Advertisement